These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8822079)

  • 1. Octreotide in malignant intestinal obstruction.
    Pandha HS; Waxman J
    Anticancer Drugs; 1996 Jan; 7 Suppl 1():5-10. PubMed ID: 8822079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to use octreotide for malignant bowel obstruction.
    Ripamonti C; Mercadante S
    J Support Oncol; 2004; 2(4):357-64. PubMed ID: 15357519
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of octreotide in malignant bowel obstruction.
    Krammer LM
    Oncol Nurs Forum; 1999 Jun; 26(5):831-2. PubMed ID: 10382174
    [No Abstract]   [Full Text] [Related]  

  • 4. The challenge of treating malignant bowel obstruction.
    J Support Oncol; 2006 Feb; 4(2):83-4. PubMed ID: 16499129
    [No Abstract]   [Full Text] [Related]  

  • 5. Radiological imaging change in a malignant bowel obstruction patient treated with octreotide.
    Shinjo T; Kagami R
    Support Care Cancer; 2009 Jun; 17(6):753-5. PubMed ID: 19277723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide for malignant bowel obstruction: twenty years after.
    Mercadante S; Porzio G
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):388-92. PubMed ID: 22277783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
    Mangili G; Franchi M; Mariani A; Zanaboni F; Rabaiotti E; Frigerio L; Bolis PF; Ferrari A
    Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of somatostatin and octreotide in bowel obstruction: pre-clinical and clinical results.
    Ripamonti C; Panzeri C; Groff L; Galeazzi G; Boffi R
    Tumori; 2001; 87(1):1-9. PubMed ID: 11669548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer.
    Jatoi A; Podratz KC; Gill P; Hartmann LC
    J Support Oncol; 2004; 2(4):323-34; discussion 334-7. PubMed ID: 15357517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of treatment-related intermittent partial small bowel obstruction: the use of octreotide.
    Myers J; Tamber A; Farhadian M
    J Pain Symptom Manage; 2010 Apr; 39(4):e1-3. PubMed ID: 20153136
    [No Abstract]   [Full Text] [Related]  

  • 11. Octreotide in pediatric patients.
    Heikenen JB; Pohl JF; Werlin SL; Bucuvalas JC
    J Pediatr Gastroenterol Nutr; 2002 Nov; 35(5):600-9. PubMed ID: 12454572
    [No Abstract]   [Full Text] [Related]  

  • 12. Practice Patterns of Medications for Patients With Malignant Bowel Obstruction Using a Nationwide Claims Database and the Association Between Treatment Outcomes and Concomitant Use of H
    Minoura T; Takeuchi M; Morita T; Kawakami K
    J Pain Symptom Manage; 2018 Feb; 55(2):413-419.e2. PubMed ID: 29122616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic portal venous gas: a rare complication of malignant bowel obstruction during the administration of octreotide.
    Maeda I; Tsuneto S; Yasui Y; Ueda Y; Kimura T
    J Pain Symptom Manage; 2014 Feb; 47(2):e2-5. PubMed ID: 24388125
    [No Abstract]   [Full Text] [Related]  

  • 14. Octreotide.
    Murphy E; Prommer EE; Mihalyo M; Wilcock A
    J Pain Symptom Manage; 2010 Jul; 40(1):142-8. PubMed ID: 21634046
    [No Abstract]   [Full Text] [Related]  

  • 15. [The therapeutic applications of octreotide].
    Carrera-Hueso FJ; Carrera-Hueso JA; Llorente I
    Med Clin (Barc); 1996 Apr; 106(13):505-16. PubMed ID: 8992134
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.
    Mercadante S; Ripamonti C; Casuccio A; Zecca E; Groff L
    Support Care Cancer; 2000 May; 8(3):188-91. PubMed ID: 10789958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Octreotide prevents the pathological alterations of bowel obstruction in cancer patients.
    Mercadante S; Avola G; Maddaloni S; Salamone G; Aragona F; Rodolico V
    Support Care Cancer; 1996 Sep; 4(5):393-4. PubMed ID: 8883235
    [No Abstract]   [Full Text] [Related]  

  • 18. Octreotide may prevent definitive intestinal obstruction.
    Mercadante S; Kargar J; Nicolosi G
    J Pain Symptom Manage; 1997 Jun; 13(6):352-5. PubMed ID: 9204656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.
    Currow DC; Quinn S; Agar M; Fazekas B; Hardy J; McCaffrey N; Eckermann S; Abernethy AP; Clark K
    J Pain Symptom Manage; 2015 May; 49(5):814-21. PubMed ID: 25462210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Editor's commentary: Clinical use of somatostatin].
    Tulassay Z
    Orv Hetil; 2013 Sep; 154(39):1526. PubMed ID: 24058096
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.